Abstract: There are provided an aqueous shellac coating agent comprising shellac, a basic amino acid and/or a basic phosphate as well as a production process therefor; a coated food and a coated drug that have been coated with such a coating agent; a glazing composition for oil-based confectionary which is in a liquid form and comprises an aqueous shellac solution (A) containing shellac, a basic amino acid and/or a basic based confectionary in which this glazing composition is applied, to oil-based confectionary to be glazed, thereby generating a glaze; and glazed oil-based confectionary produced using this process for glazing oil-based confectionary.

Abstract: A film coating composition comprises polyvinyl alcohol and talc, and a content of the talc is 50 to 86% by mass based on 100% by mass of the total solid components of the film coating composition. A film consists of the film coating composition, and a tablet comprises the film.

Abstract: There are provided an aqueous-shellac coating agent comprising shellac, a basic amino acid and/or a basic phosphate, as well as a production process therefor; a coated food and a coated drug that have been coated with such a coating agent; a glazing.

Abstract: There are provided an aqueous shellac coating agent comprising shellac, a basic amino acid and/or a basic phosphate, as well as a production process therefor; a coated food and a coated drug that have been coated with such a coating agent; a glazing composition for oil-based confectionary which is in a liquid form and comprises an aqueous shellac solution (A) containing shellac, a basic amino acid and/or a basic phosphate dissolved in water, a thickener (B), and/or a sugar (C); a process for glazing oil-based confectionary in which this glazing composition is applied to oil-based confectionary to be glazed, thereby generating a glaze; and glazed oil-based confectionary produced using this process for glazing oil-based confectionary.

Abstract: The present invention relates to drugs and foods produced by applying a method whereby a biological activity can be efficiently exerted in the case of orally administering a biologically active protein.

Abstract: A process for making a stable pharmaceutical preparation of prostaglandin E compounds and/or 15R forms thereof is diclosed.Prostagladin E compounds and 15R forms thereof are know to have useful pharmacological actions even if they are used in a vary small amounts. However, they are extremely unstable and, therefore, considerably difficult in application for routine clinical purposes.In order to remove this difficulty, prostagladin E compounds and 15R forms thereof are formulated into a stable preparation by filling a hard capsule with a solution or a suspension thereof.

Abstract: A preparation containing an active form of vitamin D.sub.3 which is stabilized by incorporation of an amino acid that is neither one containing a sulfur atom or an acid amino group in its structure, nor an acidic amino acid, nor a salt of a basic amino acid is disclosed. Examples of said amino acids that may be used as stabilizers of the active form of vitamin D.sub.3 include neutral amino acids such as alanine, valine, proline, phenylalanine, tryptophan, leucine, isoleucine, glycine and serine, and basic amino acids such as lysine, arginine and histidine.

Abstract: A storage-stable sucralfate-containing preparation which maintains its ability, even after extended periods of time, to form a viscous, sticky, paste-like material in the presence of gastric secretions is disclosed as well as the method of making same.

Abstract: A prolonged-action multiple-layer tablet having an increased rate of dissolution of the active ingredient from a given point of time onward is disclosed. The tablet comprises layer A made of an intimate mixture of a water-insoluble wax that has an average particle size of 10 .mu.m or less and which is solid at ordinary temperatures, a disintegrator and a binder, and layer B made of an intimate mixture of a water-insoluble wax that has an average particle size of 10 .mu.m or less and which is solid at ordinary temperatures, a disintegrator, a binder and the active ingredient. In the tablet, a quick-release layer containing the active ingredient may be formed on either layer A or B.

Abstract: A gelatin covering for a substrate such as a food or drug incorporating the use of caramel from which substances with a molecular weight up to 10,000 have been removed. The caramel does not cause the water solubility of the gelatin covering to be lowered with the passage of time.

Abstract: A terephthalic acid monoamide derivative of the formula: ##STR1## (wherein R is a straight- or branched-chain lower alkyl group; R' and R" may be the same or different, and represent a hydrogen atom, or a straight- or branched-chain lower alkyl group) or pharmaceutically acceptable salts thereof are disclosed. A process for preparing such terephthalic acid monoamide derivative or its salts, as well as an anti-allergic agent containing such derivative or its salts as an effective ingredient are also disclosed.

Abstract: A compound of the formula ##STR1## is useful for treating circulatory diseases.